Cardioprotective Effect of Selective Estrogen Receptor Modulator Raloxifene Are Mediated by Heme Oxygenase in Estrogen-Deficient Rat

Figure 5

Myeloperoxidase activity in the cardiac left ventricle. Myeloperoxidase activity (MPO; expressed as mU/mg protein) in the cardiac left ventricle (LV) in ovary-intact, ovariectomized (OVX), and estrogen- (E₂: 0.10 mg/kg/day, 2 weeks orally, once daily) or RAL-treated (RAL 0.33: 0.33 mg/kg/day, RAL 1: 1.0 mg/kg/day, 2 weeks, orally, once daily) OVX rats. The intact + SnPP, OVX + SnPP, E2 + SnPP, RAL 0.33 + SnPP, and RAL 1 + SnPP columns show the actions of SnPP pretreatment (30 μg/kg 24 h and 1 h prior to the measurement). Data are expressed as means ± S.E.M. of the results on a minimum of 10 rats per group. Statistical significance: (A) as compared with the ovary-intact group. (B) as compared with the OVX group without treatment.